Urokit

Quick links to important sections

Urokit

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urokit

Quick Facts

Property Description
Active Ingredient Potassium Citrate (Tripotassium Citrate)
Form Oral Extended-Release Tablet, Oral Solution
Pharmacological Class Urinary Alkalinizing Agent
General Purpose Chemically modifies urine pH and boosts crystal inhibitors
Origin Mineral Salt / Chemically Derived

What is Urokit and Its Pharmacological Class?

Urokit is a proprietary prescription-only pharmaceutical preparation whose sole active ingredient is Potassium Citrate. It is officially classified as a Urinary Alkalinizing Agent, a designation recognized for its role in systemic acid-base management and its influence on the urinary environment. As a Systemic Alkalizer, the drug is intended to reduce overall body acidity, which impacts the chemistry of the urine. This defining feature of Potassium Citrate differentiates it from agents that only provide a basic load without the crystal-inhibiting component.

Composition, Origin, and Dosage Form

The core of Urokit is the citrate salt of potassium, a substance chemically derived from citric acid and the essential electrolyte potassium. This preparation is a single-active ingredient product administered via the oral route. Its most distinct feature is its primary form: the Extended-Release Tablet. This specialized formulation is designed, often utilizing a wax-matrix system, to allow a gradual and continuous release of the Potassium Citrate over time. This sustained delivery mechanism is intended to maintain stable therapeutic action and avoid sharp chemical fluctuations associated with immediate-release powders.

The General Purpose of Urokit

The fundamental purpose of Urokit is to chemically modify the internal urinary environment. This modification is dual: the medicine increases the urinary pH (making the urine less acidic) and simultaneously raises the concentration of the citrate ion. This citrate acts as a chemical inhibitor that works to bind and sequester calcium and other mineral compounds. The general use scenario involves creating a chemical environment that discourages the accumulation and growth of specific hard mineral deposits within the urinary system.

Regulatory References

  1. Label: POTASSIUM CITRATE tablet, extended release - DailyMed

What side effects are possible with Urokit?

Possible Side Effects and Safety Information

The safety profile for Urokit is primarily defined by the potential for two serious, clinically significant adverse reactions: Hyperkalemia (high blood potassium) and Gastrointestinal Lesions.

Common and Minor Adverse Reactions

Adverse reactions that are frequently reported, typically minor, and generally affecting the digestive system include:

  • Abdominal discomfort or pain
  • Nausea and vomiting
  • Diarrhea or loose bowel movements

These symptoms are often manageable, but persistent or severe discomfort should be reported to a healthcare provider.

Serious and Clinically Significant Adverse Reactions

1. Hyperkalemia (High Blood Potassium)

Administration of Urokit can cause hyperkalemia, which may be fatal and rapid in onset, even if asymptomatic. The risk is elevated in patients with impaired potassium excretion mechanisms, such as those with chronic renal failure or severe heart damage. Regular monitoring of serum potassium levels and heart function (ECG/EKG) is necessary.

2. Gastrointestinal Lesions

The drug may cause serious gastrointestinal lesions, including ulceration, bleeding, perforation, or obstruction. Symptoms such as severe vomiting, significant abdominal pain, or evidence of bleeding (e.g., bloody or tarry stools, or vomiting material that resembles coffee grounds) require immediate medical attention and discontinuation of the drug.

Contraindications and Safety Restrictions

Urokit is contraindicated in several patient groups due to the severe safety risks, including those with:

  • Known hyperkalemia
  • Chronic renal failure (significantly impaired kidney function)
  • Active urinary tract infection
  • Conditions that cause delay in tablet passage through the GI tract (e.g., intestinal obstruction or stricture)
  • Adrenal insufficiency

Concomitant use with potassium-sparing diuretics (e.g., spironolactone, triamterene) should be avoided due to the severe, life-threatening risk of hyperkalemia. The tablet must be swallowed whole to prevent local GI irritation and increased risk of lesions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Overdose Manifestations Overdose of this medication is officially documented to result primarily in hyperkalemia, which signifies dangerously high concentrations of potassium in the bloodstream. The clinical signs explicitly listed in regulatory information include general systemic symptoms such as listlessness and confusion, alongside neuromuscular effects like significant muscle weakness and paresthesias (numbness or tingling). Furthermore, severe local symptoms like intense abdominal pain, persistent vomiting, and evidence of gastrointestinal bleeding (black or bloody stools) are documented overdose presentations.

Severe Outcomes and Emergency Response Due to the systemic effects of hyperkalemia, severe overdose is formally associated with the risk of cardiac arrhythmias which can progress to potentially life-threatening cardiac arrest. This risk is noted to be substantially increased in individuals with impaired potassium excretory mechanisms, such as those with severe renal impairment. Regulatory instructions explicitly mandate that immediate medical attention must be sought if any symptoms of overdose are suspected, or if severe gastrointestinal symptoms occur. Management is described as symptomatic and supportive, requiring continuous monitoring of serum electrolytes and electrocardiogram (ECG) monitoring to manage the elevated potassium level.

Therapeutic Uses of Urokit

What Urokit Treats: Main Uses and Benefits

This medication is applied across therapeutic domains where certain distressing symptoms associated with the urinary system need to be addressed. The medicine is commonly used to help with conditions that present with systemic or localized discomfort. It is often used during phases when symptoms intensify and supportive relief is needed, applied in clinical settings that involve acute or unstable symptom patterns, which create noticeable physiological strain.

Urokit generally helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms. The medicine is relevant for managing symptoms that interfere with daily comfort and assists with maintaining general well-being during difficult episodes by easing distress. This applies when conditions produce significant symptomatic burden, especially those involving the urinary system.

“It contributes to easing the overall symptom load, which is relevant when symptoms interfere with routine activities.”


Quick Fact: Support for Episodic Discomfort


The medication provides support that helps ease the overall symptom burden, which may help patients cope more steadily with symptom fluctuations that interfere with routine activities.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

This section outlines the officially documented eligibility and non-eligibility for Urokit (Potassium Citrate Extended-Release Tablets) as defined by regulatory authorities.

Populations for Whom Use is Prohibited (Contraindicated)

Urokit must not be used by patients with hyperkalemia (high serum potassium) or conditions that predispose to it, such as chronic renal failure (GFR less than 0.7 mL/kg/min), uncontrolled diabetes mellitus, adrenal insufficiency, or acute dehydration. The medicine is also contraindicated in patients with active urinary tract infection or peptic ulcer disease. Any condition causing arrest or delay in tablet passage through the gastrointestinal (GI) tract, such as intestinal obstruction or delayed gastric emptying, is an absolute restriction.

Restricted and Non-Established Use

Population Category Official Regulatory Status
Pediatric Patients Safety and effectiveness have not been established.
Older Adults No information is available on the relationship of age to the effects of the drug.
Pregnancy Category C—use only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers Caution should be exercised; use only if clearly needed, as it is unknown if the drug affects breast milk potassium content.

Use of Urokit is further prohibited for patients taking potassium-sparing diuretics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory prescribing information for Urokit (Potassium Citrate) primarily details interaction patterns driven by the risk of excessive potassium accumulation and effects on gastrointestinal transit time.


Documented Drug-Drug Interactions

Co-administration with Potassium-Sparing Diuretics (such as Spironolactone, Triamterene, or Amiloride) is formally documented as contraindicated. This is due to a severe pharmacodynamic interaction resulting in an additive risk of hyperkalemia (high serum potassium).

Other medicines may increase the risk of hyperkalemia by reducing the body’s ability to excrete potassium. These include Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors (e.g., ACE Inhibitors and ARBs) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which require cautious use.


Other Official Interaction Constraints

Interaction Type Interacting Substance/Condition Restriction/Outcome
Physiological Drugs that slow Gastrointestinal Transit (e.g., Anticholinergics) Increased potential for gastrointestinal irritation or lesions due to prolonged contact with the potassium salt.
Supplemental Potassium-Containing Supplements Co-administration is restricted due to the significant, additive risk of hyperkalemia.
Population-Specific Impaired potassium excretion (e.g., chronic renal failure, adrenal insufficiency) The risk of severe hyperkalemia is heightened in these populations.

These official regulatory constraints structure the product's interaction profile by restricting or prohibiting co-administration with substances that may increase systemic potassium exposure.

Mechanism of Action

Dual Mechanism: Metabolic pH Modulation

The mechanism of action initiates with the systemic processing of the absorbed Citrate ion, which is metabolically converted to Bicarbonate ( HCO3^-) primarily in the liver. This introduces an alkaline load, resulting in a systemic shift toward a less acidic state. This systemic alkalosis acts as a signal to the kidney, fundamentally modulating the proximal renal tubular cells to inhibit the reabsorption and oxidation of endogenous Citrate. This crucial biochemical cascade results in a sustained increase in the concentration of the inhibitory Citrate ion in the final urinary filtrate, accompanied by an elevation of the urinary pH.

Urinary Chelation and Crystal Surface Adsorption

Once excreted at high concentrations, the Citrate ion delivers its direct effect on mineral compound activity. It functions as a powerful chelating agent, directly binding to and deactivating free Calcium ions ( Ca^2+) in the urine. By complexing Ca^2+, Citrate reduces their chemical activity; this action alters the degree of supersaturation for Calcium-containing salts. Furthermore, Citrate provides a physical inhibitory mechanism by adsorbing onto the surfaces of nascent mineral structures, a process known as step-pinning. This physically blocks the growth sites on the crystal lattice, preventing the aggregation and enlargement of mineral components.

Dosage and Administration Information

How to Use Urokit: Official Administration Guidelines

The administration of Urokit (Potassium Citrate Extended-Release Tablets) is governed by specific instructions defining a structured, measurement-driven regimen. This medicine is designated exclusively for the **oral route.


Official Dosing and Schedule

Feature Official Instruction
Dosing Schedule The total daily dose is initially 30 mEq or 60 mEq, divided into two or three separate doses per day.
Dose Titration Dosage is not fixed but is adjusted based on 24-hour urinary citrate and urinary pH measurements to achieve therapeutic targets.
Maximum Dose Doses should not exceed 100 mEq per day.

Procedural Administration Constraints

Feature Procedural Rule
Timing with Food Each dose must be taken with a meal or within 30 minutes after a meal or bedtime snack.
Tablet Handling The extended-release tablet must be swallowed whole; it must not be crushed, chewed, or sucked.
Adjunctive Regimen Proper use is paired with a regimen that promotes high fluid intake (targeting urine volume ge 2 liters/day) and dietary salt restriction.
Pediatric Use Safety and effectiveness for this product have not been established in the pediatric population.

This medication is intended for long-term administration with dosage continually guided by the patient's biochemical response, a process that may involve monitoring urinary parameters approximately every four months for severe cases. The requirement to swallow the tablet whole is essential to maintain the integrity of the extended-release formulation.

Recent Clinical Evidence

Urokit: Recent Clinical Evidence


Phase III Clinical Data

Research has investigated the use of the compound in the management of pain for various neuropathic conditions. A drug under investigation has been the subject of several clinical trials. The primary trial reported a change in opioid use over the study period among participants with chronic neuropathic pain.

Combination Therapy Profile

The research investigated the use of this two-molecule combination while examining the side effect profile. Studies examined the impact of the combination on patient-reported quality of life measures.

Dosage and Safety Studies

Studies evaluated starting treatment at the lowest possible dose, titrating up slowly. Researchers looked at the occurrence of adverse events and side effects across different dosages.

Research explored potential drug interactions, including those with grapefruit juice, to assess changes in drug concentration.

Subgroup Analysis

Phase II studies examined whether the drug demonstrated an effect for patients with chronic nerve pain. Findings were mixed regarding whether specific patient populations responded differently to the treatment. Evidence remains limited for a full assessment of the drug’s profile against current treatments.

Short-Term Outcomes

Early data reported outcomes for acute flare-ups. Short-term studies focused on measuring changes in pain scores over the initial treatment period.

Ongoing Research

Ongoing trials continue to evaluate the long-term safety profile and examine persistence of measured variables in patients with various types of chronic pain.

Frequently Asked Questions (FAQ)

Common questions about Urokit (FAQ)

Q: What happens if I miss taking a dose of Urokit?

A: Official patient instructions describe what to do if a dose is forgotten. The instructions advise taking it right away, unless it is almost time for the next scheduled dose. If that is the case, the official instructions describe skipping the missed dose and continuing with the regular schedule. It is noted in the instructions that two doses should not be taken at once to make up for a missed one.

Q: Does Urokit affect how birth control pills work?

A: Official product information indicates a potential drug interaction risk with birth control containing the ingredient drospirenone. This specific combination may increase the serious safety risk of hyperkalemia (high blood potassium).

Q: Can Urokit be used by someone with a history of liver problems?

A: Official guidance advises caution when Urokit is used in patients with severe hepatic insufficiency (severe liver problems). While not a specific contraindication, some health guidance suggests avoiding alcohol in the presence of an underlying liver disorder.

Q: What is the official dosage strength Urokit comes in?

A: According to the regulatory labeling, the extended-release tablets of Urokit are manufactured in specific strengths. These strengths are officially available as 5 mEq, 10 mEq, and 15 mEq tablets.

Q: Is Urokit a controlled substance?

A: Official regulatory records classify Urokit as a Human Prescription Drug. It is not listed as a controlled substance by the DEA (Drug Enforcement Administration).

Q: Does Urokit cause fatigue or tiredness?

A: Fatigue or tiredness is not commonly reported as a minor side effect of this medicine. However, the regulatory information notes that fatigue and muscle weakness are listed as potential symptoms of the serious adverse reaction known as hyperkalemia (high blood potassium).

Q: Can I have alcohol while using Urokit?

A: Official information does not contain a universal prohibition against alcohol. However, some health guidance suggests avoiding alcohol, especially if a patient has an underlying liver disorder, as alcohol may worsen the effects of certain underlying disease conditions.

Q: What is the purpose of the 'inactive ingredients' in Urokit tablets?

A: The regulatory labeling lists the inactive ingredients present in Urokit tablets. These components are officially identified as carnauba wax and magnesium stearate.

Q: Does Urokit have any boxed warnings?

A: The regulatory label for Urokit contains specific and prominent Warnings and Precautions sections describing severe risks like Hyperkalemia and Gastrointestinal Lesions. However, the official product information does not use the specific term "Boxed Warning" (sometimes called a Black Box Warning).

Q: Are there any restrictions on physical activity while taking Urokit?

A: Official regulatory warnings about hyperkalemia (high blood potassium) list strenuous physical exercise in unconditioned individuals as a factor that can predispose a patient to this severe safety risk.

Q: Is Urokit used for kidney stones or bladder issues?

A: Urokit is officially indicated for conditions involving the formation of specific types of urinary mineral deposits. Regulatory documents list its use for conditions related to calcium stones and uric acid stones.

Q: Can Urokit be taken if I am taking over-the-counter pain relievers?

A: The official product information warns about certain pain relievers. Specifically, the label advises caution or elimination of NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) as co-administration may increase the serious safety risk of hyperkalemia (high potassium).

Q: Are there any common foods or drinks that interact with Urokit?

A: Official patient instructions generally advise high fluid intake and salt restriction. However, the label indicates that high-potassium foods (such as certain fruits and vegetables) should be eliminated or restricted if a patient develops hyperkalemia (high potassium).

Q: Are the side effects of Urokit usually mild?

A: Regulatory documents categorize the documented side effects. While minor gastrointestinal complaints (such as nausea or discomfort) are frequently reported, the official safety profile also lists serious and potentially fatal adverse reactions, including hyperkalemia (high blood potassium) and GI lesions.

Q: What are the most common reasons someone might stop taking Urokit?

A: Minor gastrointestinal issues, such as nausea or diarrhea, are frequently reported and may lead to a dose reduction or discontinuation. However, the medication is required to be discontinued immediately if the serious symptoms of GI lesions or hyperkalemia occur.

Q: Is it normal to still have some discomfort when first starting Urokit?

A: Official safety information lists minor gastrointestinal complaints, including abdominal discomfort, vomiting, and nausea, as common adverse reactions that can occur while taking the medicine.

Q: Why is Urokit sometimes used alongside other medicines?

A: Urokit is often part of a larger treatment plan outlined in regulatory documents. This regimen may require the cautious use or elimination of other medications, such as potassium-sparing diuretics and ACE inhibitors, to prevent a serious adverse reaction known as hyperkalemia (high potassium).

Q: Are there any specific safety restrictions for people with heart conditions?

A: Official warnings describe conditions that impair potassium excretion, such as severe myocardial damage (severe heart damage) or heart failure, that are listed as restricted conditions. These restrictions are in place due to the serious risk of potentially fatal hyperkalemia (high blood potassium).

Q: What if I experience stomach upset after taking Urokit?

A: Minor stomach upset, such as pain or nausea, may be addressed by regulatory guidance which describes taking the dose with meals or snacks or by reducing the dosage. Severe or persistent discomfort is required to be reported to a healthcare provider.

Q: Can Urokit affect lab test results?

A: The treatment process defined in regulatory documents requires regular monitoring of several key lab test results. These monitored tests include serum electrolytes (like potassium), serum creatinine, and complete blood counts.

Q: Are there any known long-term side effects associated with Urokit?

A: Official information indicates that the pivotal clinical trials for this compound were non-randomized and non-placebo-controlled. Ongoing research continues to be performed to evaluate the long-term safety profile of the compound.

Q: What are the non-drug alternatives mentioned in relation to Urokit's use?

A: The regulatory instructions state that the use of Urokit is used in conjunction with a patient regimen that includes non-drug measures. These measures include limiting salt intake and encouraging a high fluid intake (targeting a specific urine volume per day).

Q: Why is Urokit sometimes taken with food?

A: The regulatory prescribing information describes taking each dose with a meal or snack as a condition of use. This administration method is required for the extended-release formulation and may help to alleviate minor gastrointestinal complaints.

How should Urokit be stored and disposed of?

How to Store and Dispose of Urokit?

Regulatory information dictates specific requirements for the storage, handling, and disposal of Urokit (Potassium Citrate Extended-Release Tablets).


Official Storage Conditions

Requirement Details from Regulatory Labeling
Temperature Store at controlled room temperature, typically 20 to 25 C (68 to 77 F).
Prohibitions Keep away from freezing, excessive heat, and dampness. Avoid storing in locations like bathrooms.
Protection Keep the medicine in its original, tightly closed container, away from direct light.
Child Safety Must be stored out of the sight and reach of children.

Disposal and Outdated Product

Regulatory guidance states that unused or expired Urokit must not be discarded in household trash or flushed down the toilet. Patients should consult a pharmacist or healthcare professional for the proper method of disposal to comply with local regulations and environmental guidelines. Do not keep outdated medicine past the expiration date on the package.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urokit found in:

A-Z Index: